Resmed Inc. revenue $1.43B, quarter ended Mar 31, 2026
Resmed Inc. reported $1.43B of revenue in the quarter ended Mar 31, 2026, +10.8% on the quarter ended Mar 31, 2025.
Quarterly revenue, quarter ended Mar 31, 2026 $1.43B +10.8% year over year +$139.67M against $1.29B for the quarter ended Mar 31, 2025
Every RMD quarter JMM stores, on a real time axis
What the RMD record says, and what to quote from it
Growth is speeding up, from +9.1% to +10.8%, and +16.0% for the quarter ended Sep 30, 2023 is still the high mark of this record.
The last 6 comparable prints run +16.0%, +7.2%, +11.1%, +7.9%, +9.1%, +10.8%, so the latest rate is 1.7 points above the one before it and the rate has risen at each of the last 2 steps. Read the run rather than the last print: a single quarter's rate moves on the base it is measured against, and the base is a quarter of Resmed Inc.'s trading a year earlier, not a smooth line.
The period stored before this one ended Sep 30, 2025, about 2 quarters earlier, so a step against it would not describe a quarter of trading. SEC builds its quarterly frames from the values a filer tags, and most filers tag no standalone fourth quarter: it is reported inside the annual filing as part of the year.
These quarters do not close a fiscal year. The annual report in RMD's filing history carries the year as Resmed Inc. reports it.
RMD quarterly revenue, filing by filing
| Period ended | Quarterly revenue | Year over year | Filed | Evidence |
|---|---|---|---|---|
| 10-Q | $1.4B | +10.8% vs $1.3B, period ended Mar 31, 2025 | Open filing | |
| 10-Q | $1.3B | +9.1% vs $1.2B, period ended Sep 30, 2024 | Open filing | |
| 10-Q | $1.3B | +7.9% vs $1.2B, period ended Mar 31, 2024 | Open filing | |
| 10-Q | $1.2B | +11.1% vs $1.1B, period ended Sep 30, 2023 | Open filing | |
| 10-Q | $1.2B | +7.2% vs $1.1B, period ended Mar 31, 2023 | Open filing | |
| 10-Q | $1.1B | +16.0% vs $950.3M, period ended Sep 30, 2022 | Open filing | |
| 10-Q | $1.1B | Not stored no quarter one year earlier in the stored set | Open filing | |
| 10-Q | $950.3M | Not stored no quarter one year earlier in the stored set | Open filing |
Every row is the SEC concept RevenueFromContractWithCustomerExcludingAssessedTax, read from
the SEC company facts API by the JMM collector,
checked Aug 10, 2026. The change column is year over year and names the exact period it was measured
against, because these periods are not contiguous: a change against whichever row happens to sit below would compare
quarters up to three years apart. Earlier rows carry the accession SEC attributes the value to, which can be a later
filing that restated the period, so only the most recent row's 31-day gap is a reporting delay.
RMD against every other Surgical & Medical Instruments & Apparatus filer JMM covers
- MMM 3M Co.MMM $6.5Bperiod ended Jun 30, 2026
- BSX Boston Scientific Corp.BSX $5.4Bperiod ended Jun 30, 2026
- RMD Resmed Inc.RMD, this page $1.4Bperiod ended Mar 31, 2026
- DXCM Dexcom Inc.DXCM $1.3Bperiod ended Jun 30, 2026
- WST West Pharmaceutical Services Inc.WST $872.3Mperiod ended Jun 30, 2026
Each issuer's latest stored quarter, in USD, for every filer JMM covers under SEC SIC 3841. Fiscal calendars differ, so these periods end on different dates: the bars compare scale, not a shared quarter. Coverage is JMM's, not the classification's, so this is not the whole industry.
Continue from the Resmed Inc. record
Reproduce any row in the table below from the raw XBRL frames, period by period.
CalculatorAnnualize the growth between any two of these quartersPaste a starting and ending value from the table to get a compound annual rate, before and after CPI-U inflation.
GuideWhat the XBRL tag behind this figure actually measuresWhy two issuers reporting the same business can carry different revenue concepts, and what that changes about comparing them.